Jubilant Pharmova · NSE: JUBLPHARMA · BSE: 530019

Q4 FY23 results · Jan–Mar 2023

Jubilant Pharmova reported revenue from operations of ₹1,678.00 crore (up 10.8% from Q4 FY22) and net loss of ₹100.51 crore for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.

Consolidated · ₹ crore
Item	Q4 FY23	Q4 FY22	YoY	Q3 FY23	QoQ
Revenue from operations	1,678.00	1,514.44	+10.8%	1,552.51	+8.1%
Other income	4.45	10.13	−56.1%	9.47	−53.0%
Total income	1,682.45	1,524.57	+10.4%	1,561.98	+7.7%
Profit before share of associates & JVs and tax	(103.12)	104.33	Turned loss	10.38	Turned loss
Share of profit/(loss) of associates & JVs	16.71	1.34		(1.65)
Net profit for the period	(100.51)	59.09	Turned loss	(16.04)	Loss widened
Attributable to shareholders of the company	(97.84)	59.55	Turned loss	(15.67)	Loss widened
EPS, basic (₹)	(6.15)	3.74	Turned loss	(0.98)	Loss widened
Net margin (%)	-6.0	3.9		-1.0

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q4 FY23	Q4 FY22	YoY	Q3 FY23	QoQ
Revenue from operations	199.84	28.79	+594.1%	182.74	+9.4%
Other income	13.66	7.10	+92.4%	7.87	+73.6%
Total income	213.50	35.89	+494.9%	190.61	+12.0%
Profit before tax	(1.23)	(4.14)	Loss narrowed	(11.14)	Loss narrowed
Net profit for the period	(30.86)	(3.11)	Loss widened	(5.89)	Loss widened
EPS, basic (₹)	(1.94)	(0.19)	Loss widened	(0.37)	Loss widened
Net margin (%)	-15.4	-10.8		-3.2

Consolidated

Filed with BSE: 30 May 2023, 18:03 IST
Board meeting: 29 May 2023
Period: 01 Jan 2023 to 31 Mar 2023
Review status: Audited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 30 May 2023, 18:03 IST
Board meeting: 29 May 2023
Period: 01 Jan 2023 to 31 Mar 2023
Review status: Audited
Source: XBRL filing on BSE